TITLE

NRTI Backbone in HIV Treatment: Will it Remain Relevant?

AUTHOR(S)
Tressler, Randall; Godfrey, Catherine
PUB. DATE
September 2012
SOURCE
Drugs;2012, Vol. 72 Issue 16, p2051
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Nucleoside reverse transcriptase inhibitors (NRTIs) remain a critical component of therapy for HIV-infected patients. The drugs are effective, relatively inexpensive and an important component of antiretroviral therapy (ART), particularly in areas where the introduction of effective therapy has been delayed. They are an essential part of initial therapy for HIV and for prevention of mother-to-child transmission; however, toxicities and resistance may limit their use. The role for pre-exposure prophylaxis (PrEP) to reduce sexual transmission of HIV is still undefined, but this use may have a significant impact on NRTI resistance worldwide, most particularly in areas where subtype C predominates. With increasing prevalence of resistant HIV, the approval of new agents that are effective against resistant virus, and those that use novel cellular targets, are essential. Large studies are now in progress examining the safety and efficacy of NRTI-sparing regimens, but results are not currently available. NRTIs may lose relevance in the not distant future unless steps are put in place to reduce the development and spread of NRTI- resistant viruses, and new NRTIs with minimal toxicity are developed that have a novel resistance profile. This article describes the principal NRTIs, their mechanism of action, and resistance and selected toxicities of the class and of the individual drugs.
ACCESSION #
83364597

 

Related Articles

  • Azvudine, A Novel Nucleoside Reverse Transcriptase Inhibitor Showed Good Drug Combination Features and Better Inhibition on Drug-Resistant Strains than Lamivudine In Vitro. Wang, Rui-Rui; Yang, Qing-Hua; Luo, Rong-Hua; Peng, You-Mei; Dai, Shao-Xing; Zhang, Xing-Jie; Chen, Huan; Cui, Xue-Qing; Liu, Ya-Juan; Huang, Jing-Fei; Chang, Jun-Biao; Zheng, Yong-Tang // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Azvudine is a novel nucleoside reverse transcriptase inhibitor with antiviral activity on human immunodeficiency virus, hepatitis B virus and hepatitis C virus. Here we reported the in vitro activity of azvudine against HIV-1 and HIV-2 when used alone or in combination with other antiretroviral...

  • Rilpivirine: A second-generation nonnucleoside reverse transcriptase inhibitor. James, Christopher; Preininger, Lee; Sweet, Meryn // American Journal of Health-System Pharmacy;5/15/2012, Vol. 69 Issue 10, p857 

    Purpose. The pharmacology, pharmacokinetics, drug interactions, clinical efficacy, adverse effects, dosage and administration, and place in therapy of rilpivirine are reviewed. Summary. Rilpivirine is a human immunodeficiency virus type 1 (HIV-1)-specific nonnucleoside reverse transcriptase...

  • Recent Advances in the DABOs Family as Potent HIV-1 non-Nucleoside Reverse Transcriptase Inhibitors. Mingyan Yu; Erkang Fan; Jingde Wu; Xinyong Liu // Current Medicinal Chemistry;Jun2011, Vol. 18 Issue 16, p2376 

    No abstract available.

  • Etravirine: A Guide to Its Use in Treatment-Experienced Pediatric Patients with HIV-1 Infection in the US. Lyseng-Williamson, Katherine A. // Pediatric Drugs;2012, Vol. 14 Issue 5, p345 

    Etravirine (Intelence®), an oral next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), is approved for the treatment of HIV-1 infection in treatment-experienced patients. In the US, the approved use of etravirine in patients who have evidence of viral replication and harbor...

  • Zidovudine/Lamivudine for HIV-1 Infection Contributes to Limb Fat Loss. van Vonderen, Marit G. A.; van Agtmael, Michiel A.; Hassink, Elly A. M.; Milinkovic, Ana; Brinkman, Kees; Geerlings, Suzanne E.; Ristola, Matti; van Eeden, Arne; Danner, Sven A.; Reiss, Peter // PLoS ONE;2009, Vol. 4 Issue 5, p1 

    Background: Lipoatrophy is known to be associated with stavudine as part of the treatment for HIV infection, but it is less clear if this serious side effect is also related to other nucleoside reverse transcriptase inhibitors like zidovudine. We aimed to determine whether zidovudine-sparing...

  • Clinical Implications of HIV-1 Minority Variants. Li, Jonathan Z.; Kuritzkes, Daniel R. // Clinical Infectious Diseases;Jun2013, Vol. 56 Issue 11, p1667 

    Low-frequency HIV variants are increasingly recognized as a key factor that increases the risk of HIV treatment failure. This article will provide a review of HIV minority variants, including their demonstrated clinical impact and areas of controversy.Technologic advances in human...

  • Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China. Min Chen; Yanling Ma; Song Duan; Hui Xing; Shitang Yao; Yingzhen Su; Hongbing Luo; Li Yang; Huichao Chen; Liru Fu; Aijuan Qu; Chin-Yih Ou; Manhong Jia; Lin Lu // BMC Infectious Diseases;2012, Vol. 12 Issue 1, p382 

    Background: The emergence of an HIV-1 epidemic in China was first recognized in Dehong, western Yunnan. Due to its geographic location, Dehong contributed greatly in bridging HIV-1 epidemics in Southeast Asia and China through drug trafficking and injection drug use; and also extensively to the...

  • Efavirenz.  // AHFS Consumer Medication Information;Oct2019, p1 

    Efavirenz is used with other medications to treat human immunodeficiency virus (HIV) infection in patients with or without acquired immunodeficiency syndrome (AIDS). Efavirenz is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by slowing the...

  • Abacavir.  // AHFS Consumer Medication Information;Oct2019, p1 

    Abacavir is used in combination with other medications to treat human immunodeficiency virus (HIV) infection. Abacavir is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by slowing the spread of HIV in the body. Abacavir does not cure HIV infection...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics